Educational dose math only — not medical advice, not a product recommendation, and not a pass/fail on whether a supplement will work for you.
0 100% 150%+

—

Enter label dose

Trial reference

From your label

Per-day total — not per serving unless you take one serving

Enter your label dose — the gauge updates instantly.

Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials.

Educational only — not medical advice. Disclaimer.

NIH DSLD market slice

Median0.8 g
Products3,121
Below99%

Bulk CSV dump 16 January 2026 · label entries through 2025. Disclosed amounts only — proprietary blends without gram weights excluded.

Trial floors

Primary

Menafra 2022 (vasculogenic ED) · 6 g over 3 months (medium evidence) · Benefit shown — Multicentre double-blind RCT (51 arginine / 47 placebo) in vasculogenic ED. IIEF-6 and cavernous peak systolic velocity both improved, but only 24% reached scores compatible with no ED — mostly the mild-ED subgroup. High daily gram burden vs citrulline trials.

Label reading notes

  • Six grams per day is a large capsule/powder load — check serving count on the label.
  • Low-dose "NO booster" arginine (1–2 g/day) sits far below the vasculogenic ED trial dose and will not match that evidence on the label.
  • Do not stack with PDE5 inhibitors or nitrates without clinician sign-off. GI side effects are common at effective gram doses.